Notes:

1. The above unaudited consolidated financial results of Aurobindo Pharma Limited ("the Company") including its subsidiaries (collectively known as "the Group") and its associates and joint ventures have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013 ("the Act"), read with the relevant rules issued thereunder and other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. The above unaudited consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of the Act and Companies (Indian Accounting Standards) Rules, 2015, as amended.
3. The above unaudited consolidated financial results of the Group as reviewed by the Audit Committee have been approved by the Board of Directors at its meeting held on August 4, 2025. The results for the quarter ended June 30, 2025 have been reviewed by our statutory auditors. The statutory auditors of the Company have issued an unmodified conclusion in respect of the limited review for the quarter ended June 30, 2025.
4. The Group operates in only one reportable segment viz., 'Pharmaceuticals ' in accordance with Ind AS 108, "Operating Segment".
5. "During the quarter ended June 30, 2025:
   (i) The Company, incorporated a step-down subsidiary, CuraTeQ Biologics B.V., Netherlands through CuraTeQ Biologics Private Limited, India (wholly owned subsidiary) on May 28, 2025.
   (ii) The Company, incorporated a step-down subsidiary, Cresedemo Pharma LLC through Aurobindo Pharma USA Inc., (wholly owned subsidiary) on June 13, 2025.
6. Aurobindo Pharma USA Inc., a wholly owned subsidiary of the Company, has entered into a definitive agreement on July 30, 2025 to acquire 100% of membership interest in Lannett Company LLC. The proposed transaction is subject to certain regulatory approvals. Accordingly, no financial impact has arisen in this quarter.
7. "The Board of Directors of the Parent company at their meeting held on July 18, 2024, approved buyback of 5,136,986 fully paid-up equity shares of face value of ₹ 1 each (representing 0.88% of the total number of equity share shares of the parent company) for an aggregate value not exceeding ₹ 7,500.0 million (buyback size) (excluding transaction cost and tax on buyback) at a maximum buyback price of ₹ 1,460/- per equity share. Upon completion of the buyback, the Parent company extinguished the equity shares in compliance with applicable rules and regulations.

Consequently, the paid up equity share capital of the Parent company was reduced by ₹ 5.1 million. The aggregate amount paid for buyback was ₹ 9,302.4 million including tax and related expenses."

8. The figures for the quarter ended March 31, 2025 are the balancing figures of the audited financials for the year ended March 31, 2025 and unaudited year to date published results for the nine months ended December 31, 2024, which were subject to limited review by the statutory auditors.
9. The Board of Directors at their meeting held on August 4, 2025 declared an interim dividend of ₹ 4 per equity share (Face value ₹ 1).